What is a stock summary page? Click here for an overview.
Business Description
Lyra Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US55234L1052
Share Class Description:
LYRA: Ordinary SharesCompare
Compare
Traded in other countries / regions
LYRA.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2020-05-01Description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.18 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 2.97 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -12.49 | |||||
| Beneish M-Score | -1.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.9 | |||||
| 3-Year EBITDA Growth Rate | 34.4 | |||||
| 3-Year EPS without NRI Growth Rate | 35.9 | |||||
| 3-Year FCF Growth Rate | 20.9 | |||||
| 3-Year Book Growth Rate | -59.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 6.04 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 163.97 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.58 | |||||
| 9-Day RSI | 36.86 | |||||
| 14-Day RSI | 38.29 | |||||
| 3-1 Month Momentum % | 21.88 | |||||
| 6-1 Month Momentum % | -23.3 | |||||
| 12-1 Month Momentum % | -96.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | |||||
| Quick Ratio | 3.41 | |||||
| Cash Ratio | 3.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -71.4 | |||||
| Shareholder Yield % | -318.32 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3959.13 | |||||
| Net Margin % | -6090.94 | |||||
| FCF Margin % | -4716.36 | |||||
| ROE % | -203.02 | |||||
| ROA % | -89.19 | |||||
| ROIC % | -149.06 | |||||
| 3-Year ROIIC % | -120.58 | |||||
| ROC (Joel Greenblatt) % | -200.45 | |||||
| ROCE % | -69.23 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.16 | |||||
| PB Ratio | 0.88 | |||||
| Price-to-Tangible-Book | 0.88 | |||||
| EV-to-EBIT | -0.07 | |||||
| EV-to-EBITDA | -0.08 | |||||
| EV-to-Revenue | 2.96 | |||||
| EV-to-Forward-Revenue | 2.95 | |||||
| EV-to-FCF | -0.07 | |||||
| Price-to-GF-Value | 0.09 | |||||
| Earnings Yield (Greenblatt) % | -1428.57 | |||||
| FCF Yield % | -692.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LYRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lyra Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.534 | ||
| EPS (TTM) ($) | -1.43 | ||
| Beta | -0.21 | ||
| 3-Year Sharpe Ratio | -0.26 | ||
| 3-Year Sortino Ratio | -0.35 | ||
| Volatility % | 105.21 | ||
| 14-Day RSI | 38.29 | ||
| 14-Day ATR ($) | 0.015538 | ||
| 20-Day SMA ($) | 0.18249 | ||
| 12-1 Month Momentum % | -96.63 | ||
| 52-Week Range ($) | 0.144 - 6.79 | ||
| Shares Outstanding (Mil) | 65.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lyra Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lyra Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lyra Therapeutics Inc Frequently Asked Questions
What is Lyra Therapeutics Inc(LYRA)'s stock price today?
The current price of LYRA is $0.16. The 52 week high of LYRA is $6.79 and 52 week low is $0.14.
When is next earnings date of Lyra Therapeutics Inc(LYRA)?
The next earnings date of Lyra Therapeutics Inc(LYRA) is 2025-04-30 Est..
Does Lyra Therapeutics Inc(LYRA) pay dividends? If so, how much?
Lyra Therapeutics Inc(LYRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers